Federal agencies are shifting money toward treatment, recovery and public safety, while California continues to support fentanyl test strips and syringe services. Here is what changes, who pays and what remains uncertain.
The Trump administration is changing how federal money can be used to address drug use and homelessness, creating a growing policy divide between Washington and California.
Federal agencies are restricting the use of certain federal grant dollars for harm-reduction supplies, including fentanyl and xylazine test strips and sterile syringes. At the same time, California continues to operate state-supported programs that provide fentanyl test strips and support syringe services.
For Los Angeles, that creates a practical question that goes beyond the political debate:
If Washington stops paying for certain harm-reduction services, how much will California and local governments have to pay instead?
The answer could affect public-health programs, nonprofit providers, homelessness services and communities dealing with both overdose and public-safety concerns.
On April 24, 2026, the Substance Abuse and Mental Health Services Administration, or SAMHSA, issued updated guidance on which supplies and services can be supported with SAMHSA funding.
The agency said the federal government was continuing a shift away from harm reduction and practices it considers to facilitate illicit drug use. The guidance identifies supplies and services that can no longer be supported with SAMHSA funds, including fentanyl and xylazine test strips, sterile syringes and certain safer-smoking supplies.
But there is an important distinction:
The federal government has not banned Americans from possessing fentanyl test strips.
The policy restricts the use of particular federal grant dollars to purchase or distribute certain supplies.
SAMHSA’s guidance continues to allow federal funding for overdose-response services, including opioid overdose reversal medications such as naloxone and nalmefene, as well as overdose education and training.
That means the effect in California depends partly on which programs rely on federal funding and which have access to state, local or other funding sources.
And California still has a state-funded system for fentanyl test strips.
California is moving in a different direction
California’s Department of Health Care Services continues to operate the Naloxone Distribution Project, which allows qualified organizations to request free naloxone and fentanyl test strips.
DHCS says the program’s funding comes from state, federal and opioid settlement funds and remains subject to the state’s budget and available funding.
That means the federal restrictions do not automatically eliminate California’s fentanyl test-strip program.
As of August 2026, DHCS continues to allow eligible organizations to request fentanyl test strips through the program. The strips are provided free to approved applicants.
The program reaches well beyond traditional harm-reduction organizations.
California says eligible recipients can include county agencies, community organizations, hospitals, first responders, schools, local governments and substance-use-disorder treatment facilities.
That makes the federal change potentially important to a much wider network of California health and community organizations.
California also protected syringe access
The federal funding shift comes as California is maintaining legal protections for syringe access.
California Department of Public Health guidance issued in 2026 explains that Assembly Bill 309 removed the sunset date from state provisions allowing physicians and pharmacists to furnish syringes without a prescription to adults 18 and older.
California’s Department of Public Health also continues to authorize syringe services programs.
The state maintains a directory of authorized programs across California and says organizations can seek authorization through local governments or directly through CDPH.
The state’s 2026 guidance says syringe services programs are intended to address injection-related public-health risks and reduce the transmission of HIV, viral hepatitis and other blood-borne diseases. It also addresses syringe collection and disposal. California’s 2026 syringe-services fact sheet
So while Washington is restricting certain federal funding for harm reduction, California is maintaining a state-level infrastructure that supports these services.
That is the central policy collision.
The issue is bigger than fentanyl test strips
The fight over test strips is part of a broader change in federal policy.
In July 2025, President Donald Trump signed Executive Order 14321, titled “Ending Crime and Disorder on America’s Streets.”
The order directed federal agencies to change how homelessness and related programs address addiction, mental illness, public disorder and encampments. It also directed agencies to revise federal programs, where legally permissible, including provisions involving data collection and coordination with law enforcement.
HUD has since moved to reshape the federal homelessness funding system.
In its June 1 announcement, HUD said its $4.04 billion Fiscal Year 2026 Continuum of Care funding opportunity would shift the program toward recovery and self-sufficiency.
HUD said the new funding opportunity would support organizations providing treatment and recovery services and would prohibit funding the widespread distribution of illicit-drug paraphernalia. It also announced $1.3 billion in new projects, with priority for transitional housing and supportive-service projects.
An earlier HUD announcement previewed the same broader shift, emphasizing transitional housing, supportive services, substance-use-disorder treatment, mental-health treatment and employment assistance.
HUD also encouraged partnerships involving homelessness providers, treatment organizations, faith-based groups and law enforcement.
The result is a much broader federal shift:
Washington is placing greater emphasis on treatment, recovery, self-sufficiency and public safety.
California continues to maintain programs designed to reduce the immediate health risks associated with drug use while connecting people with healthcare and other services.
Los Angeles is where the policy debate becomes practical
For Los Angeles, these competing approaches intersect with problems residents already see every day.
The region is dealing simultaneously with homelessness, fentanyl exposure, overdose, public drug use, discarded syringes, neighborhood safety concerns and demands for more treatment capacity.
That makes the question of federal funding particularly important.
If a nonprofit or public-health agency previously relied on federal money to purchase certain supplies, it may now have to identify another source of funding.
That could mean:
- State appropriations
- County funding
- City funding
- Opioid settlement dollars
- Private philanthropy
- Other permissible federal or non-federal sources
California’s DHCS explicitly says its Naloxone Distribution Project relies on multiple funding sources, including state, federal and opioid settlement funds.
The important question is therefore not simply whether California supports harm reduction.
It is how much California is willing and able to spend to maintain it as federal priorities change.
California’s overdose picture makes the debate more complicated
The federal funding shift also comes as overdose deaths have begun declining nationally.
Parriva recently examined that trend in “US Overdose Deaths Fell for a Second Year, but New Risks Are Emerging”, while an earlier Parriva report, “U.S. Drug Overdose Deaths Are Falling, but Fentanyl Still Devastates Latino and California Communities,” examined the continuing impact of fentanyl.
Those stories are part of the context for understanding why the policy debate is changing.
A decline in overdose deaths does not mean fentanyl or the broader overdose crisis has disappeared.
But it gives the Trump administration a stronger argument for shifting federal resources toward long-term treatment and recovery rather than maintaining an emergency-response model.
Public-health officials and harm-reduction advocates can make the opposite argument: as long as fentanyl and other unpredictable substances remain in the illicit drug supply, overdose-prevention tools remain necessary.
That disagreement is now shaping how governments decide where scarce public dollars should go.
Why supporters defend harm reduction
Supporters of harm reduction generally do not argue that people should remain addicted.
Their argument is that people who are using drugs may face immediate risks before they are ready or able to enter treatment.
Fentanyl test strips are designed to identify the presence of fentanyl in drug samples. California DHCS says the strips can be used with substances including cocaine, methamphetamine and heroin, as well as pills, powders and injectables.
California also says its syringe-services system is intended to reduce the spread of infectious diseases and connect people who use drugs with healthcare and other services.
From that perspective, harm reduction is not necessarily an alternative to treatment.
It can be viewed as a way to reduce immediate risk and maintain contact with people who may eventually enter treatment.
Why critics reject the approach
Critics see the issue differently.
They argue that providing supplies associated with drug use can reduce the pressure to stop using drugs and may unintentionally normalize or facilitate continued drug use.
They also point to neighborhood concerns involving discarded syringes, public drug use, encampments and the effects of open-air drug markets on residents and businesses.
Those concerns are now reflected in federal policy.
HUD’s new homelessness strategy emphasizes treatment, recovery and self-sufficiency while rejecting what the administration describes as the previous federal emphasis on “Housing First” and harm reduction.
The administration’s argument is that public resources should address what it considers the underlying causes of homelessness, particularly addiction and mental illness, rather than simply managing the consequences.
The California question: Who pays?
This may ultimately be the most consequential question for California.
The state’s fentanyl test-strip program remains operational, but DHCS makes clear that it depends on available funding and normal state budget processes.
That means a continued federal retreat from harm reduction could place more pressure on California’s other funding sources.
The state has opioid settlement money available for addiction and overdose-response efforts, but those funds are not an unlimited replacement for every federal grant.
Counties and nonprofit organizations may therefore have to compete for available resources while also responding to increased demands for treatment, homelessness services and public safety.
For Los Angeles, that could eventually become a budget question:
How much should taxpayers spend on preventing overdose and disease today, and how much should be directed toward treatment and long-term recovery?
That is not a question Washington can answer for California.
Several developments are worth watching.
1. Whether California replaces lost federal funding
The state’s current programs remain active, but their future scale will depend on appropriations, settlement funds and other available resources.
2. Whether local providers lose federal support
The impact will vary by organization. A provider that depends heavily on federal grants could face a very different situation from one financed primarily through California or local funding.
3. Whether Los Angeles increases its own spending
Los Angeles and other local governments may face pressure to fill gaps if state or federal resources become less available.
4. Whether the federal homelessness changes survive legal challenges
The implementation of federal homelessness policy remains an important area to watch. The safest way to understand the current situation is to distinguish between policies announced by HUD, rules currently being implemented and any provisions later altered by courts.
5. Whether California and Washington continue moving in opposite directions
This may be the biggest story.
California has maintained its harm-reduction infrastructure while Washington is restructuring federal funding around treatment, recovery and public order.
That creates the possibility of a growing funding and policy gap between the two governments.
What Californians should understand
The federal government has not outlawed fentanyl test strips in California.
Instead, the Trump administration has restricted the use of certain federal funds for harm-reduction supplies and is reshaping homelessness assistance around treatment, recovery and public safety.
California continues to provide fentanyl test strips through its Naloxone Distribution Project and continues to authorize syringe services programs.
That means the immediate question for Californians is not whether harm reduction suddenly disappears.
The question is how much of it California can continue to finance if federal priorities keep moving in another direction.
For Los Angeles, the answer could affect more than public-health agencies.
It could shape homelessness programs, nonprofit budgets, treatment services, neighborhood policies and the debate over how government should respond to people struggling with addiction.
Washington has changed the rules for its money.
Now California has to decide how much it is willing to spend to maintain its own approach.
What readers should watch
Federal funding: Which California organizations lose access to federal dollars?
State funding: Will California increase funding for fentanyl test strips, syringe services and treatment?
Los Angeles: Will city or county officials have to fill any funding gaps?
Treatment capacity: Can California expand detoxification, medication treatment and residential recovery services quickly enough to meet increased demand?
Public safety: Can local governments address discarded syringes, public drug use and neighborhood concerns while maintaining access to overdose-prevention services?
The answers will determine whether California’s harm-reduction model can continue at its current scale, or whether the federal shift eventually forces a much larger change.
